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LETTERS TO THE EDITOR 
Hazards of administering blood cardioplegic 
solution directly into the heart: Cardioplegic 
solutions are not equal 
To the Editor: 
Recently a cardiac surgeon asked me what would 
happen if he injected the cardioplegic solution that my 
colleagues and I have described irectly into the heart, 
rather than mixing it with blood. The answer was that I did 
not know, although I suspected that this procedure might 
severely damage the sarcolemmal membrane and produce 
irreversible cardiac injury. That is what occurred. Of note, 
this same complication occurred many years ago with the 
Melrose solution, and the problem has since been cor- 
rected. 
This rare but potentially ethal complication leads me to 
the following discussion. The potential problem, even 
when using myocardial solutions with blood from the 
pump, led my colleagues and me to address this problem 
in the JOURNAL in 1994. ~ 
Table I shows the infused versus cardiovascular dose of 
crystalloid blood cardioplegic solution (i.e., St. Thomas' 
Hospital), and Table II shows the infused versus cardio- 
vascular dose of blood cardioplegic solution including the 
crystalloid component. Please note that the solution de- 
scribed in Table I enters the heart, whereas the solution 
described in Table II must be diluted with blood to reach 
the heart. Delivery of the latter solution (Table II) to the 
heart without mixing it with blood will likely strip off the 
sarcolemmal membrane and lead to the complication that 
I just described. 
For those who wish to try blood cardioplegia, they may 
start by adding potassium to the solution described in 
Table I to achieve a cardioplegic concentration f potas- 
sium chloride. This method will increase the concentra- 
tion of potassium in the cardioplegic solution and de- 
crease the concentration f the other components. I do 
not know how the heart will do, as I do not use this 
solution. 
Conversely, never infuse the solution described in Table 
II into the heart. The need to start with a crystalloid 
component is not a problem with blood cardioplegia, 
because the heart is never ischemic when the solution is 
flowing both antegradely and retrogradely, as in our 
practice. For that reason, the delay in arrest is less 
problematic than when crystalloid cardioplegic solution is 
given. However, infusion via the coronary sinus is useful, 
because the amount of solution passing obstructive vessels 
is decreased with the heart supported by cardiopulmonary 
bypass, and the proximal artery is occluded. 
The figures in Tables I and II are simply for comparison 
of the different cardioplegic solutions, but they should 
serve to estimate the potential problems with infusing 
crystalloid solutions into the heart when they are meant o 
be mixed with a blood cardioplegic component. 
I hope this brief reminder will be useful to those 
physicians who may wish to stop the heart with a solution 
Table L St. Thomas'  Hospital solution with crystalloid component  
St. Thomas' Hospital solution - St. Thomas' Hospital solution delivered 
NaCt 110.0 mmol/L NaCI 110.0 mmol/L 
KC1 16.0 mmol/L KC1 16.0 mmol/L 
MgC12 16.0 mmol/L MgC12 16.0 mmol/L 
CaCI2 1.2 mmol/L CaC12 1.2 mmol/L 
NaHCO 3 10.0 mmol/L NaHCO3 10.0 mmol/L 
pH -7.8 pH -7.8 
Osmo~larity 324 mOsm/L Osmolarity 324 mOsm/L 
Total 1000 ml Total 1000 ml 
Table IL Blood cardioplegic solution with crystalloid component, mixed 4.'1 with blood 
Cardioplegic omposition + Blood = BCP delivered 
Tham (0.3 mol/L) 225 ml pH 7.4 pH 7.5-7.6 
CPD 225 ml Ca + + 1.2 mmol/L Ca + + 0.15 mmol/L 
Glu/Asp 250 ml Glu/Asp -0 mmol/L Glu/Asp 13 mmol/L 
KC1 (2 mEq/ml) 40 ml K ÷ -4 mEq/L K ÷ 20-25 mEq/L 
D50W 40 ml Osmolarity 280 mOsm/L Osmolarity 380-400 mOsm/L 
5% Dextrose 220 ml BS --i00 mg/dl BS >400 mg/dt 
Total 1000 ml Total 4000 ml Total 5000 ml 
BCP, Blood cardioplegia; Tham, tromethamine; CPD, citrate-phosphate-dextrose; Glu/Asp, glutamate/aspartate; D5OW, 50% dextrose inwater; BS, buffered 
saline; 4:1 - four to one blood/crystalloid ratio. 
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that is intended to be mixed with blood in a 4:1 ratio. 
Clearly, the same problem would occur with any other 
solution that uses our formulations to stop the heart and 
can be used safely as the warm reperfusate. 
Gerald D. Buckberg, MD 
University of California at Los Angeles 
School of Medicine 
Los Angeles, CA 90095-1741 
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Nitric oxide: Unjustified credit? 
To the Editor: 
We were interested to read of the experience of Mertes 
and associates, 1 because we have had similar experience 
with the use of inhaled nitric oxide for the implantation of 
the HeartMate 1000P left ventricular assist system 
(LVAS) (Thermo Cardiosystems, Inc., Woburn, Mass.). 
Our patient, similar to theirs, was 54 years old with 
end-stage idiopathic dilated cardiomyopathy but with 
additional renal and hepatic failure. We also had difficulty 
weaning the patient from cardiopulmonary b pass (CPB), 
being unable to increase the LVAS flows to more than 2 
L/rain because of poor right ventricular function. The 
introduction of inhaled nitric oxide at a rate of 80 ppm 
resulted in immediate improvement of LVAS flow rates to 
more than 4 L/rain and improvement in oxygenation, and 
CPB was subsequently successfully terminated. The effect 
of nitric oxide was demonstrated by a significant fall in 
LVAS flows (to 2.5 L/rain) when inhaled nitric oxide was 
temporarily withdrawn (for change of cylinder and trans- 
port to the intensive care unit). Despite a subsequent 
promising 48-hour period when nitric oxide was able to be 
withdrawn, and despite LVAS flow rates of more than 5 
L/rain, progressive hepatic and multiple organ failure 
developed, from which the patient died 2 weeks later. 
We are enthusiastic about he role of nitric oxide in this 
situation for a number of theoretical reasons. First, in- 
haled nitric oxide is specific to the pulmonary vasculature, 
giving rise to decreased pulmonary vascular esistance. 2 
This reduction in right ventricular afterload is likely to be 
of benefit in the management of postimplantation right 
heart failure provided that one can expect he pulmonary 
vascular esistance to decrease with time; this one would 
expect if the elevated resistance is caused by left ventric- 
ular dysfunction or if the resistance has been transiently 
exacerbated byperioperative blood transfusion. However, 
if the postimplantation right ventricular failure is due to 
poor preoperative right ventricular function or if there has 
been a perioperative decline in right ventricular function 
(i.e., poor myocardial protection), then the outlook for 
these patients may be poor and they may require the 
addition of a right ventricular assist device with all of its 
attendant risks. Additionally, in this situation of right 
ventricular failure, tricuspid regurgitation is almost inev- 
itable, and the reduced impedance to forward flow en- 
sures a smaller tricuspid regurgitant fraction and more 
efficient output from the dilated right ventricle. Second, 
unlike other vasodilators, nitric oxide has minimal sys- 
temic action because of rapid inactivation by hemoglobin. 3 
Third, the use of inhaled nitric oxide, in contrast to intrave- 
nous pulmonary vasodilators, improves perfusion of venti- 
lated alveoli and decreases the shuntfraction. 4 Last, unlike 
prostacyclin, inhaled nitric oxide has no demonstrable effect 
on hemostasis n vivo. In cases in which anticoagulation is 
unnecessary (as in the HeartMate LVAS), the lack of 
antihemostatic a tivity is an advantage. 
Having expressed our enthusiasm for inhaled nitric 
oxide on anecdotal nd theoretical grounds, we argue that 
the case presented by Mertes and associates I has insuffi- 
cient support for the conclusion that improvement was 
due to the use of inhaled nitric oxide. We are surprised to 
read that improvement occurred only after 30 minutes of 
nitric oxide administration ata rate of 50 ppm. From our 
experience, as well as other reports 5 of the use of inhaled 
nitric oxide in this and other situations (after transplan- 
tation and after mitral valve operations), we would have 
expected an almost immediate response. No further data 
to support he proposed effect of nitric oxide are offered, 
such as the effect of termination or interruption of nitric 
oxide. To the critical observer, the improvement may have 
been due to a spontaneous recovery in right ventricular 
function while the patient was supported by a further 
period of normothermic CPB, quite apart from delayed 
effects of concomitant treatment (e.g., diuretics, inodila- 
tors) that may have been additionally used. 
In summary, we share the enthusiasm for the use of 
inhaled nitric oxide in the management of right ventricu- 
lar failure after the insertion of a totally implantable 
LVAS. However, we do not accept he conclusion, on the 
data presented for this case, that inhaled nitric oxide was 
responsible for the improvement seen. In addition, al- 
though nitric oxide is extremely valuable in rapidly lower- 
ing pulmonary vascular esistance, unless the increased 
resistance is due to a reversible cause, the prospects for 
successful bridge to transplantation with an implantable 
LVAS alone may be poor. 
S. J. George, MRCP, FRCA 
J. J. M. Black, FRCS 
M. J. Boscoe, FRCA 
Harefield, United Kingdom 
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